Subgroup analyses of adverse events by age, sex, race and prior BOTOX@ treatment showed no statistically significant differences between the treatment groups. Reviewer’s Comments and Conclusions on studies: Clinical Tr - Clinical study design - Document - PDFSEARCH.IO

First Page	Meta Content
	Subgroup analyses of adverse events by age, sex, race and prior BOTOX@ treatment showed no statistically significant differences between the treatment groups. Reviewer’s Comments and Conclusions on studies: Clinical Tr Add to Reading List Open Document File Size: 2,21 MB Share Result on Facebook Company Subgroup / Allergan / / Country United States / / / Event FDA Phase / / Facility For laboratory / / IndustryTerm dose/injection site / injection site / treated / / MedicalCondition Known allergy / disease / disorder / Infection / facial nerve palsy / EatonLambert syndrome / diagnosed myasthenia gravis / muscle weakness / pain in the face / congenital anomaly/birth defect / amyotrophic lateral sclerosis / / MedicalTreatment elective surgery / BOTOX / contraception / antibiotics / / Organization FDA / International Criminal Court / / Position investigator / physician / efficacy variables investigator / Treatments Investigator / / Product BOTOX@ injection / G15 / / SocialTag Science Pharmacology Design of experiments Evaluation methods Pharmaceutical industry Botulinum toxin Methadone Clinical trial Placebo-controlled study Clinical research

Subgroup analyses of adverse events by age, sex, race and prior BOTOX@ treatment showed no statistically significant differences between the treatment groups. Reviewer’s Comments and Conclusions on studies: Clinical TrAdd to Reading List